https://www.macrotrends.net/stocks/charts/IMNN/imunon/total-assets
Imunon Total Assets 2012-2026 | IMNN | MacroTrends
Imunon total assets from 2012 to 2026. Total assets can be defined as the sum of all assets on a company's balance sheet.
total assetsimunon20122026macrotrends
https://www.finanznachrichten.de/nachrichten-2026-03/68088340-imunon-inc-imunon-reports-2025-financial-results-and-provides-business-update-highlighting-significant-progress-with-pivotal-phase-3-study-399.htm
Imunon, Inc.: IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting...
IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with...
financial resultsbusiness updateimunonincreports
https://www.buzzsprout.com/236855/episodes/18571959-stacy-lindborg-ceo-of-imunon
Stacy Lindborg: CEO of Imunon
Stacy Lindborg, CEO of Imunon, shares her insights about leadership in biopharma and how Imunon is working to develop medicines that harness the building...
stacylindborgceoimunon
https://www.globenewswire.com/fr/news-release/2025/06/05/3094318/0/en/imunon-to-present-at-the-zacks-scr-life-sciences-virtual-investor-forum-on-june-12th.html
IMUNON to Present at the Zacks SCR Life Sciences Virtual
LAWRENCEVILLE, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated...
at thelife sciencesimunonpresentzacks
https://www.globenewswire.com/news-release/2025/04/21/3064621/0/en/IMUNON-Announces-IMNN-001-Abstract-Accepted-for-Oral-Presentation-at-2025-ASCO-Annual-Meeting.html
IMUNON Announces IMNN-001 Abstract Accepted for Oral
Highly promising survival data from OVATION 2 Study of treatment of newly diagnosed advanced ovarian cancer to be presented Initiation of Phase 3 trial...
imunonannounces001abstractaccepted
https://www.globenewswire.com/de/news-release/2025/12/29/3211040/0/en/IMUNON-2025-A-TRANSFORMATIVE-YEAR-OF-SIGNIFICANT-CLINICAL-ADVANCES-LOOKING-AHEAD-TO-2026.html
IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL
Enrollment in the Pivotal Phase 3 OVATION 3 Study Advances Company Toward Future BLA Filing New Data from MRD Study Reinforces IMNN-001's Promise as a...
year ofimunon2025transformativesignificant